RA Capital Continues Significant Share Sales, Disposing of Another $10.17M in Vor Biopharma Stock
VOR has more than doubled off its 52-week low of $2.622.
Summary
RA Capital Healthcare Fund LP, a 10% owner and director, reported selling an additional $10.17 million worth of Vor Biopharma stock, continuing a trend of significant dispositions this month.
Key Events · Ownership and Investor Activity · VOR
-
Continued Significant Sales
RA Capital Healthcare Fund LP, a 10% owner and director, sold 630,374 shares of Vor Biopharma common stock for a total value of $10,174,788 between April 17 and April 20, 2026.
-
Part of Ongoing Distribution
This transaction is the latest in a series of sales by RA Capital in April 2026, bringing their total dispositions this month to over $32 million, following previous sales reported on April 10 and April 15.
-
Post-Transaction Holdings
After these sales, RA Capital's indirect holdings in Vor Biopharma stand at 2,739,208 shares.
Analysis · VOR · Life Sciences
RA Capital Healthcare Fund LP, a 10% owner and director-affiliated entity, has continued its pattern of significant share sales in Vor Biopharma. This latest disposition of over $10.17 million in common stock between April 17-20, 2026, follows previous sales totaling over $22 million earlier in April. The cumulative selling pressure from a major institutional investor and director could signal a lack of conviction or a strategic portfolio rebalancing, potentially weighing on investor sentiment. This ongoing distribution occurs after Vor Biopharma's recent strategic pivot and a $75 million private placement in March 2026, suggesting that even with new capital, a key investor is reducing exposure.
At the time of this filing, VOR was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $741M. The 52-week trading range was $2.62 to $65.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.